このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Protagonist Therapeutics バランスシートの健全性
財務の健全性 基準チェック /66
Protagonist Therapeuticsの総株主資本は$560.4M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$629.3Mと$68.8Mです。 Protagonist Therapeuticsの EBIT は$148.7Mで、利息カバレッジ比率-8.9です。現金および短期投資は$322.6Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | -8.9x |
| 現金 | US$322.64m |
| エクイティ | US$560.44m |
| 負債合計 | US$68.83m |
| 総資産 | US$629.28m |
財務の健全性に関する最新情報
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09財務状況分析
短期負債: PTGXの 短期資産 ( $627.6M ) が 短期負債 ( $39.9M ) を超えています。
長期負債: PTGXの短期資産 ( $627.6M ) が 長期負債 ( $28.9M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: PTGXは負債がありません。
負債の削減: PTGX 5 年前には負債がありませんでした。
債務返済能力: PTGXには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: PTGXには負債がないため、利息支払い の負担は問題になりません。